What emerging drug delivery systems are being explored for Dry Eye Disease treatment?

Dry eye disease (DED) is a common condition where the eyes do not produce enough tears or the tears evaporate too quickly. Current treatments like eye drops often need to be used frequently and may not stay on the eye long enough. Researchers are exploring new drug delivery systems that can keep medication on the eye longer, reduce side effects, and target the underlying inflammation. These systems include nanoparticles, hydrogels, liposomes, microspheres, and gene-based platforms ⁵⁸⁹.

What the research says

A 2023 review in Experimental Eye Research describes how biomaterials such as nanosystems, hydrogels, and contact lenses are being tested to deliver drugs like cyclosporin and steroids for DED. Most studies so far are in animals, showing improved drug delivery and effects, but human trials are still needed ⁸. Another 2023 review in Bioengineering highlights similar advances, including nano-systems, hydrogels, and contact lenses, as well as cell-based and regenerative therapies, noting that these approaches could offer longer-lasting relief ⁹. A separate review on immunopathology and drug delivery systems for DED discusses nanoparticles, hydrogels, liposomes, microspheres, and emerging gene-based platforms designed to enhance drug retention and target inflammation ⁵. While these systems are promising, they are still in early stages and not yet widely available for patients.

What to ask your doctor

• Are there any clinical trials near me testing new drug delivery systems for dry eye?
• Could a punctal plug or other device help my current eye drops work better?
• What are the potential benefits and risks of newer treatments like nanoparticle-based eye drops?
• How do I know if my dry eye is caused by inflammation that might respond to targeted therapies?
• Are there any long-term studies on the safety of these emerging delivery systems?